利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.032 秒)

    Methods of screening for a compound that reduces atherogenesis
    2.
    发明授权
    Methods of screening for a compound that reduces atherogenesis 失效
    筛选减少动脉粥样化形成的化合物的方法

    公开(公告)号：US08691498B2

    公开(公告)日：2014-04-08

    申请号：US11991232

    申请日：2006-08-29

    申请人： Yaron Hakak ,  David J. Unett ,  Joel Gatlin ,  Chen W. Liaw

    发明人： Yaron Hakak ,  David J. Unett ,  Joel Gatlin ,  Chen W. Liaw

    IPC分类号： C12Q1/00 ,  C12Q1/68 ,  C07K14/705

    CPC分类号： G01N33/5041 ,  A61K38/1709 ,  A61K49/0008 ,  C07K14/47 ,  C07K14/723 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/726 ,  G01N2500/00 ,  G01N2800/32 ,  G01N2800/323

    摘要： The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.

    摘要翻译： 本发明涉及使用G蛋白偶联受体（GPCR）鉴定候选化合物是否是动脉粥样硬化形成调节剂的方法。 在某些实施方案中，GPCR与Gi相连。 在某些实施方案中，GPCR是人。 本发明的激动剂可用作预防或治疗动脉粥样硬化和动脉粥样硬化疾病（包括冠状动脉疾病，心肌梗塞，外周动脉疾病和缺血性中风）的治疗剂。 本发明的激动剂另外可用作预防或治疗与MCP-1表达相关的病症的治疗剂，包括但不限于类风湿性关节炎，克罗恩病和多发性硬化症。

    GPR22 AND METHODS RELATING THERETO
    9.
    发明申请
    GPR22 AND METHODS RELATING THERETO 审中-公开
    GPR22及其相关方法

    公开(公告)号：US20090313708A1

    公开(公告)日：2009-12-17

    申请号：US12089893

    申请日：2006-10-12

    申请人： Chen W. Liaw

    发明人： Chen W. Liaw

    IPC分类号： G01N33/00 ,  C12Q1/68 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00 ,  C12P21/06 ,  C12Q1/02 ,  A01K67/00

    CPC分类号： C07K14/705

    摘要： Methods for generating an expression-enhanced GPR22 nucleic acid, as well as substituted GPR22 nucleic acids providing for enhanced expression of the encoded GPR22 polypeptide, are provided. In practicing the subject methods, a nucleic acid encoding a mammalian GPR22 receptor polypeptide (e.g., a wild-type nucleic acid) is expression-enhanced by identifying the various codons of the coding region for the GPR22 amino acid sequence and substituting nucleotides so as to enhance expression without changing the amino acid sequence of the encoded GPR22 polypeptide. Methods, compositions, and kits using the same for screening of modulators of GPR22 are also provided.

    摘要翻译： 提供了产生表达增强的GPR22核酸的方法，以及提供编码的GPR22多肽的增强表达的取代的GPR22核酸。 在实施本发明方法中，通过鉴定GPR22氨基酸序列的编码区的各种密码子并用核苷酸取代编码哺乳动物GPR22受体多肽（例如野生型核酸）的核酸，可以表达增强，从而 增强表达而不改变编码的GPR22多肽的氨基酸序列。 还提供了用于筛选GPR22调节剂的方法，组合物和试剂盒。

    Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR
    10.
    发明申请
    Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR 审中-公开
    非内源性，组成型激活的人类G蛋白偶联受体：FSHR

    公开(公告)号：US20080199888A1

    公开(公告)日：2008-08-21

    申请号：US11796432

    申请日：2007-04-27

    申请人： Chen W. Liaw

    发明人： Chen W. Liaw

    IPC分类号： C07H21/04 ,  C07K16/00 ,  C12N15/00 ,  C12N5/00 ,  C12P21/04 ,  G01N33/53

    CPC分类号： C07K14/723

    摘要： The invention disclosed in this patent document relates to transmembrane receptors, particularly to a human G protein-coupled receptor, more particularly to a follicle stimulating hormone receptor (FSHR), and most particularly to mutated (non-endogenous) versions of the human FSHR for evidence of constitutive activity.

    摘要翻译： 本专利文献中公开的发明涉及跨膜受体，特别是涉及人G蛋白偶联受体，更具体地涉及促卵泡激素受体（FSHR），特别是人FSHR的突变（非内源）版本， 组成性活动的证据。